Shenzhen Ketuoxun Technology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Shenzhen Ketuoxun Technology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include KETUOXUN. The owner is based in Longhua Dist. Shenzhen.

Donghuan 2nd Road, Sanlian Community,

010, Bldg.J1, Meili 365 Garden, No.170

Longhua Dist. Shenzhen 518000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

KETUOXUN
KETUOXUN
Registered 2024

Trademark Classifications

Shenzhen Ketuoxun Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Shenzhen Ketuoxun Technology Co., Ltd. have?

Shenzhen Ketuoxun Technology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Shenzhen Ketuoxun Technology Co., Ltd. file in?

Shenzhen Ketuoxun Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Shenzhen Ketuoxun Technology Co., Ltd.'s most well-known trademarks?

Shenzhen Ketuoxun Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as KETUOXUN. These are among 1 currently registered trademark in the portfolio.

What is Shenzhen Ketuoxun Technology Co., Ltd.'s trademark registration success rate?

Shenzhen Ketuoxun Technology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.